EU Gives Orphan Drug Status to MRG-106 for Treating T-cell Skin Lymphomas
News
The European Union has granted orphan drug status to miRagen Therapeutics’s MRG-106 for the treatment of cutaneous T-cell lymphoma (CTCL). The status is given to treatments for rare diseases. It accelerates the ... Read more